QTTB (Q32 Bio) Moat Score: 3/10 (As of Jul. 07, 2026)


QTTB Q32 Bio Inc QTTB
17 GF Score
Price $12.84
! 6 Warning Signs
View Full Analysis

What is Q32 Bio Moat Score?

Q32 Bio QTTB -1.72% 17 Moat Score is 3 as of Jul. 07, 2026. GuruFocus rates QTTB with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,395 Biotechnology companies, Q32 Bio ranks better than 75.56% on this metric.

Q32 Bio has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Q32 Bio has No Moat: Q32 Bio Inc operates in a highly competitive biotech sector with limited differentiation. It lacks significant regulatory barriers, brand strength, or cost advantages to establish a durable competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Q32 Bio might have No Moat - Very weak/transient advantages.

Q32 Bio  (NAS:QTTB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Q32 Bio Moat Score Related Terms

QTTB vs CAMP, CDXS, KROS: Moat Score Comparison

For the Biotechnology subindustry, Q32 Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Moat Score falls into.


QTTB
17GF Score
Q32 Bio Inc QTTB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Q32 Bio (QTTB) has a Moat Score of 3 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Q32 Bio ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Q32 Bio's Moat Score too high?
Q32 Bio's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Q32 Bio's value of 3 is 50% above this industry median. Based on the distribution chart, Q32 Bio ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Moat Score compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #341 out of 1395 companies for Moat Score. This places Q32 Bio in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Q32 Bio's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q32 Bio's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (QTTB) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Q32 Bio (QTTB), the current Moat Score is 3 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges DB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for QTTB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.84
Price